

## Central Nervous System Diseases

The development of new treatment options for Neuropsychiatric diseases is a key priority for Boehringer Ingelheim, evidenced by the innovative work in these areas of both its collaboration partners and the Company's own highly experienced research and development professionals.

### Indications:

Neuropsychiatric diseases including:

- Alzheimer's disease (focus: cognitive impairment and other neuropsychiatric symptoms)
- Schizophrenia (focus: negative symptoms and/or cognitive impairment)
- Depression (focus: treatment-resistant depression)
- Impulse control disorders.

### Specific partnering priorities:

- Novel approaches to modulate fundamental mechanisms and pathways involved in synaptic dysfunction and maladaptive brain circuitry as the root causes of various neuropsychiatric symptom domains; ideally, the proposed modality will include a target engagement and/or pharmacodynamic marker
- Complementary non-drug approaches (e.g. cognitive remediation).

In all these areas, we are looking for compounds and concepts from early drug discovery to pre-clinical and early clinical stages.

### Out of scope:

- Neuroprotective agents
- Monoamine uptake inhibitors or monoamine receptor modulators
- Compounds with unknown mechanism of action.

**If you share our goal of researching and developing new medications to improve the health of people around the world please join us in...**

**Working together for better health**

For more information please contact our BD&L team:

Dr. Klaus D. Mendla

[klaus.mendla@boehringer-ingelheim.com](mailto:klaus.mendla@boehringer-ingelheim.com)

Dr. Laura Corradini

[laura.corradini@boehringer-ingelheim.com](mailto:laura.corradini@boehringer-ingelheim.com)

